Mereo BioPharma Group plc

Transaction in Own Shares • Apr 26, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2896X

Mereo BioPharma Group plc

26 April 2019

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of Director Dealing

London, 26 April 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 23 April 2019, Deepa Pakianathan, a non-executive director of Mereo, received 256,734 American Depositary Shares in the Company, as set out in the following table.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

Deepa Pakianathan

2

Reason for the notification

a)

Position/status

Director

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group Plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Mereo BioPharma Group plc American Depositary Shares ("ADSs").

Each ADS represents five ordinary shares of nominal value GBP 0.003 each in Mereo BioPharma Group Plc.

ADSs - ISIN: 589492107

b)

Nature of the transaction

Issue of ADSs in consideration for the acquisition of stock in OncoMed Pharmaceuticals, Inc.  

c)

Price(s) and volume(s)

Price(s)	Volume(s)
0.127694 Stock Units in OncoMed Pharmaceuticals, Inc per ADS	256,734 ADSs

d)

Aggregated information:  volume, Price

Aggregated volume: 256,734 ADSs

Aggregated price: 2,010,542 stock units in OncoMed Pharmaceuticals, Inc.

e)

Date of the transaction

2019-04-23

f)

Place of the transaction

Outside Trading Venue.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHZQLFLKZFBBBB